Application of azide-modified hyaluronic acid in drug delivery and/or drug storage

The invention relates to application of azide-modified hyaluronic acid in drug delivery and/or drug storage. The azide modified hyaluronic acid is composed of repeated disaccharide (beta, 1-4)-gluconic acid (GlcA) and (beta, 1-3)-azide acetyl glucosamine (GlcNAz). The medicine is a DBCO modified medicine. According to the present invention, the drug delivery and/or drug storage by using the synthesized azide-modified hyaluronic acid is found and proposed for the first time, and the azide-modified hyaluronic acid can be combined with the DBCO-modified drug through the click reaction so as to achieve the drug delivery and/or drug storage purpose. The azide-modified hyaluronic acid monomer or the azide-modified hyaluronic acid hydrogel is injected near a solid tumor, after the whole-body doxorubicin prodrug DBCO-Dox is used, the azide-modified hyaluronic acid captures the doxorubicin prodrug DBCO-Dox, after the azide-modified hyaluronic acid monomer and the azide-modified hyaluronic acid hydrogel are combined, t